Milani Erase Base Blemish Control Primer

Description

No specific details regarding the Description section for SPL code 34089-3 are provided in the text.

Uses and Indications

This drug is indicated for the treatment of acne. It helps to clear existing acne blemishes and maintain clear skin by preventing the formation of new blemishes.

Dosage and Administration

Healthcare professionals are advised to ensure that the skin is thoroughly cleaned prior to the application of this product. The affected area should be covered with a thin layer of the product, applied one to three times daily, depending on the patient's needs and the physician's recommendations.

It is recommended to initiate treatment with one application per day. If the patient tolerates this initial regimen without significant adverse effects, the frequency of application may be gradually increased to two or three times daily.

In cases where the patient experiences bothersome dryness or peeling, it is advisable to reduce the frequency of application to once daily or every other day to mitigate these effects.

Contraindications

The use of this product is contraindicated in patients who are concurrently using another topical acne medication, as this may increase the risk of skin irritation and dryness. In the event of irritation, it is advised to limit the use to one topical acne medication at a time.

Warnings and Precautions

For external use only. It is imperative that this product is kept out of reach of children to prevent accidental ingestion. In the event of swallowing the product, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Healthcare professionals should be aware that the concurrent use of this product with other topical acne medications may increase the likelihood of skin irritation and dryness. To mitigate the risk of adverse effects, it is advised that only one topical acne medication be used at a time. If skin irritation occurs, the use of additional topical treatments should be discontinued.

Side Effects

For external use only. Patients should be advised to keep this product out of reach of children. In the event of accidental ingestion, medical help should be sought immediately, or contact with a Poison Control Center is recommended.

When using this product, participants may experience skin irritation and dryness, particularly if another topical acne medication is used concurrently. It is advised that only one topical acne medication be utilized at a time to minimize the risk of irritation.

Drug Interactions

The concurrent use of multiple topical acne medications may increase the risk of skin irritation and dryness. To mitigate this risk, it is advised that only one topical acne medication be used at a time. If irritation occurs, discontinuation of one of the medications is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Milani Erase Base Blemish Control Primer (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep the medication out of reach of children. In the event of accidental ingestion, immediate medical assistance or contact with a Poison Control Center is recommended.

For topical application, it is suggested to initiate treatment with one application daily. Depending on the patient's response and as directed by a healthcare professional, the frequency may be gradually increased to two or three times daily. Care should be taken to monitor for potential skin drying; if bothersome dryness or peeling occurs, the application frequency should be reduced to once daily or every other day.

Geriatric Use

Elderly patients may not have specific information regarding the use of this medication, including dosage adjustments, safety concerns, or special precautions. Therefore, healthcare providers should exercise caution when prescribing this medication to geriatric patients. It is advisable to monitor these patients closely for any potential adverse effects or changes in efficacy, given the lack of targeted data for this population.

Pregnancy

There is currently no information available regarding the use of Milani Erase Base Blemish Control Primer during pregnancy. This includes a lack of data on safety concerns, dosage modifications, or any special precautions that should be taken when considering its use in pregnant patients. Healthcare professionals are advised to exercise caution and consider the absence of data when discussing the use of this product with women of childbearing potential.

Lactation

No information related to nursing mothers or lactation is provided in the drug insert for Milani Erase Base Blemish Control Primer. Therefore, the effects on breastfed infants and the excretion of the product in breast milk are not known. Healthcare professionals should exercise caution when recommending this product to lactating mothers.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, immediate medical intervention is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical assistance or contact a Poison Control Center without delay.

Prompt action is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved, and healthcare providers should be prepared to assess and manage these symptoms accordingly.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. Continuous monitoring and evaluation are recommended to ensure patient safety and effective resolution of any complications arising from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data in these areas limits the understanding of the compound's potential effects in nonclinical settings.

Postmarketing Experience

No postmarketing experience details are provided in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication concurrently with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance is essential for ensuring the safe and effective use of the medication.

Storage and Handling

The product is supplied in a container that must be kept tightly closed to maintain its integrity. It should be stored at room temperature, away from direct light exposure to protect its quality. Once opened, the product should be discarded to ensure safety and efficacy.

Additional Clinical Information

The route of administration for the medication is topical. There are no additional details available regarding laboratory tests, abuse information, patient counseling, or postmarketing experience.

Drug Information (PDF)

This file contains official product information for Milani Erase Base Blemish Control Primer, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)